To investigate the clinical significance of the enrichment of CD133 and CD44 markers in CRC and distal margin tissues, all the patients quantified for CD133 and CD44 expression were followed‐up to a period of 24 months from the day of tumour excision. This evidence concerns the gene PROM1 and colorectal carcinoma.